NCT05164016Completed
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
This study is being done because the investigators would like to learn more about how well the COVID-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy. Primary Objective Assess the immunogenicity to COVID-19 vaccination in patients with cancer and/or transplant and cellular therapy (TCT) recipients. Secondary Objectives * Evaluate the antibodies response to COVID-19 vaccination in immunocompromised patients. * Evaluate the T cell response to COVID-19 vaccination in immunocompromised patients. Exploratory Objectives * Assess incidence and severity of COVID-19 infections by 6 months following immunization with a SARS CoV-2 vaccine. * Assess the durability immune response to COVID-19 vaccination. * Assess the immunogenicity of COVID-19 vaccination in immunocompetent children and adolescents without cancer and have not undergone transplant or received cellular therapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 21 (actual)
- First submitted
- 16 Dec 2021
- Start date
- 29 Jun 2022
- Primary completion date
- 1 May 2025
- Lead sponsor
- St. Jude Children's Research Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT05164016
What you commit to
- Study type: Observational
- Participants enrolled: 21
- From 29 Jun 2022 to the primary completion date, 1 May 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received a COVID-19 vaccine prior to enrollment (Day 0).
Who the study is looking for
- Patient receiving care at St. Jude Children's Hospital or Le Bonheur Children's Hospital
- Less than 24 years old at the time of enrollment (Day 0)
- Planning to receive a COVID-19 vaccine as part of clinical care
- Patient is one of the following:
- Diagnosed with a Hematological Malignancy (Group A), or
- Received a hematopoietic cell transplant or cellular therapy (Group B), or
- Diagnosed with a solid tumor malignancy (Group C).
- Received a solid organ transplant (Group D), or
- Does not have cancer and has not received any type of transplant (Group E)
- Willing and able to provide informed consent
Age in the registry: - to 24 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| LeBonheur Coordinator of this site? Confirm its status | Memphis | United States | Unknown status |
| Le Bonheur Coordinator of this site? Confirm its status | Memphis | United States | Unknown status |
| St. Jude Children's Research Hospital Coordinator of this site? Confirm its status | Memphis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.